Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Acurox NDA Returns To FDA Without Niacin, But With More Dosing Flexibility

This article was originally published in The Pink Sheet Daily

Executive Summary

King and Acura are refiling the abuse-resistant oxycodone, this time without the addition of vitamin B3 that FDA and an advisory panel said would do no good at stopping abuse.

You may also be interested in...

Hydrocodone Gets Advisory Committee Review, Offering Congress A Scheduling Out

FDA announces the October meeting unusually early following legislative efforts to further restrict access to the opioid pain reliever due to abuse worries.

King Aims To File New Acurox NDA In Early 2011

King Pharmaceuticals expects to file a new drug application in early 2011 for its pain drug Acurox, excluding niacin as a potential abuse deterrent, execs told investors during a first quarter earnings call May 5

Acurox Drops Niacin, But King And Acura Need New Study For Reformulation

Firms will submit NDA for a revised version of their oxycodone formulation Acurox that offers impediments to abuse by snorting or injection but does not contain niacin, which FDA says is ineffective at preventing oral abuse.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts